Posts by TJ Curioso

a pioneering surgical blood salvage technology developed at the university of strathclyde, glasgow, is set to transform the way major surgery is carried out by reducing blood loss in patients.. .

hemosep is set to revolutionise the health care sector after gaining the ce mark and receiving canadian national approval, following highly successful clinical trials in the world leading university of kirikkale university hospital in ankara, turkey.. the device is designed to recover blood spilled during open-heart and major trauma surgery and concentrate the blood cells for transfusion back to the patient.

this process, known as autotransfusion, reduces the volume of donor blood required and the problems associated with transfusion reaction.. .

TJ Curioso

A pioneering surgical blood salvage technology developed at the University of Strathclyde, Glasgow, is set to transform the way major surgery is carried out by reducing blood loss in patients.

HemoSep is set to revolutionise the health care sector after gaining the CE mark and receiving Canadian national approval, following highly successful clinical trials in the world leading University of Kirikkale University Hospital in Ankara, Turkey.

The device is designed to recover blood spilled during open-heart and major trauma surgery and concentrate the blood cells for transfusion back to the patient. This process, known as autotransfusion, reduces the volume of donor blood required and the problems associated with transfusion reaction.

Professor Terry Gourlay

Professor Terry Gourlay, who led the development of the technology at the University’s Department of Biomedical Engineering, said: “This is a fantastic example of real collaboration between the University of Strathclyde and the medical device industry to take this device from concept to clinical delivery.

“The introduction of HemoSep to the medical device field will make a significant difference to people’s lives and greatly reduce the cost and risks associated with blood transfusions. The technology has distinct advantages over traditional techniques which are not only costly but technically challenging and involve the use of a complex centrifuge and pumping apparatus by specialist technicians.

“We expect further developments in the form of a derivative of this technology for use in children undergoing open-heart surgery where the challenges of blood conservation are even more critical.”

In the clinical trials, carried out in over 100 open-heart surgery operations, the use of the HemoSep device significantly reduced the need for blood transfusions together with preservation of normal clotting mechanisms and a reduction in the inflammatory reaction often encountered after such surgical procedures.

The device consists of a blood bag which employs a chemical sponge technology and a mechanical agitator to concentrate blood sucked from the surgical site or drained from the heart-lung machine after the surgery. The separated cells are then returned to the patient by intravenous transfusion.

Bioengineer Laurie Shedden demonstrates the device

Professor Serdar Gunaydin, Head of Cardiac Surgery at the University of Kirikkale where the trials were conducted, said: “The technology is a real step forward in the field of autotransfusion for cardiac surgery, being highly effective, easy to use and associated with a reduction in the need for donor transfusion and blood loss in these patients.

“In the climate of national blood product shortages and concern for disease transmission and immunosuppression, every effort should be made to optimise blood recovery and reduce allogeneic blood usage.

“The HemoSep technology has produced impressive results, it is the easiest method we have ever used. There is no interference with the ongoing operation and product is ready to use following a very short processing time. It quickly and safely recovers substantial proteins, clotting factors and cell concentrates for all types of cardiac procedures.

“We believe this new technology will be one of the essential components of the routine heart surgery in the near future. We even think this technique may be useful for blood preservation during transplantation, orthopedics and neurosurgery.”

Further clinical trials are planned, but the CE mark means that the device will now be sold to the healthcare sector. HemoSep has been licensed to Advancis Surgical Ltd. The company will market and sell the device in all European territories, other regions which recognise the CE mark and Canada.

Mr Stephen Cotton, Advancis Surgical Ltd director of research and development, said: “We are delighted to be able to make this announcement which comes after considerable shared effort to develop this exciting product. We hope that this success will be the first of many through our collaboration with the University of Strathclyde.”

Professors Gourlay and Gunaydin will present the results of the recent clinical trials at the European Society for Artificial Organs congress in Rostock, Germany in September to correspond with Advancis’ commercial launch of the device.?

21 August 2012

http://www.strath.ac.uk/press/newsreleases/headline_648390_en.html

1

Article "Making the case for bloodless surgery"

by TJ Curioso in

making the case for bloodless surgeryaugust 20, 2012 12:12 amby rob wennemer / pittsburgh post-gazette.

jehovah's witnesses base their refusal of blood transfusions on verses in several books of the bible.

because north sider charles taze russell's teachings were the basis for those beliefs, it seems appropriate that allegheny general hospital's center for bloodless medicine and surgery continues to realize the benefits of bloodless surgery -- for everyone.. "i would say that every week we are doing two or three jehovah's witness surgeries of some kind or another," said jan c. seski, the center's medical director and director of the hospital's division of gynecological oncology.. a recent study suggests the witnesses are on to something.

TJ Curioso

Making the case for bloodless surgery

August 20, 2012 12:12 am By Rob Wennemer / Pittsburgh Post-Gazette

Jehovah's Witnesses base their refusal of blood transfusions on verses in several books of the Bible. Because North Sider Charles Taze Russell's teachings were the basis for those beliefs, it seems appropriate that Allegheny General Hospital's Center for Bloodless Medicine and Surgery continues to realize the benefits of bloodless surgery -- for everyone.

"I would say that every week we are doing two or three Jehovah's Witness surgeries of some kind or another," said Jan C. Seski, the center's medical director and director of the hospital's division of gynecological oncology.

A recent study suggests the Witnesses are on to something. In a study published last month in the Archives of Internal Medicine, doctors from the Cleveland Clinic reported that Witnesses who underwent bloodless cardiac surgery fared better than non-Witnesses in terms of infection and complication rates, length of hospital stays, and short- and long-term survival.

Although the study, which compared 322 patients of each group, focused only on cardiac surgery, many doctors report similar trends in orthopedic, gynecological and neurosurgery.

In 1962, Dr. Denton Cooley pioneered bloodless open-heart surgery on Jehovah's Witness patients in Texas. Since then, the practice has evolved to the point that many surgeons, regardless of a patient's religious beliefs, try to minimize the loss of blood each and every time they stand over the operating table.

"We've taken what we have learned in the management of the Jehovah's Witnesses and are applying it to the general medical population as a whole," said Dr. Seski. "Blood in and of itself may be lifesaving. If you have a trauma patient that comes in after a motorcycle accident and they are bleeding to death, you need to use transfusions. But if you can avoid it, in some situations you will get a better outcome."

Dr. Seski is credited as being the first to bring the techniques to Pittsburgh in 1981 after completing his fellowship at M.D. Anderson Cancer Center in Houston, Texas.

In addition to their religious convictions, many Witnesses fear the possibility of contracting blood-borne illnesses such as hepatitis or HIV/AIDS through transfusions.

"[Donated] blood is dirty -- that is the best kept secret in the world. ... It can give you all of these different infections," said William McGill, 62, of Erie, who had successful bloodless large aortic aneurysm surgery at AGH. "Offending my God was first, but when I found out how dirty [donated] blood was, whether I was a Witness or not, I would not have accepted transfusions."

As tumors are removed in surgery, cancerous cells are released into the bloodstream, Dr. Seski said. Cancer patients' weakened immune systems can have trouble handling these cells along with "foreign" antibodies and other substances from a transfusion. Immunosuppressant qualities associated with donated blood are a big reason for the increased complications and infections experienced by patients who receive transfusions, according to Dr. Seski. Such complications can lead to longer hospitalizations as well.

There is not one specific methodology used when performing bloodless surgery. Hospitals take a "whole programmatic approach," said Dr. Seski, and they must adapt to the needs of the patient. Nonetheless, certain procedures are used to increase blood counts and to prevent blood loss before, during and after surgery.

Before surgery, doctors attempt to normalize the patient's blood count, as many are anemic. Patients who are anemic do not have enough healthy red blood cells, which are responsible for providing oxygen to body tissues.

Blood counts can be raised 1 gram per week by providing the patient with iron and synthetic growth hormones such as erythropoietin, which stimulate the bone marrow to produce red blood cells. The increased speed with which doctors can now boost blood counts to a safe level for surgery is especially significant, as patients with a malignancy are far better off when operated on sooner rather than later.

A hemodilution technique pioneered by Dr. Seski and others in 1977 at M.D. Anderson is one of a number of strategies used to save blood during surgery. Preferred by Jehovah's Witnesses, it is a closed loop system that separates a patient's blood into red blood cells and clear plasma. The machine returns the plasma and a saline solution to the patient's body during surgery in order to equalize blood volume. The red blood cells are kept in the machine, however, and returned to the body at the end of surgery.

Although Jehovah's Witnesses do not allow their blood to be removed and stored prior to a surgery, they allow this technique because their blood is never technically separated from the body.

The postoperative care of a patient is also very important, as blood can continue to be lost after a surgery is complete. Blood samples, for instance, can remove up to 1 pint per week. To minimize the loss, doctors now use pediatric tubes, drawing smaller amounts of blood while still gaining the necessary data from testing.

Smaller incisions have also reduced the amount of blood lost during surgery.

"We use a laparoscopic approach, and that allows us to really get folks up sooner out of bed because they are not having pain from a big incision," said Dr. James T. McCormick, who specializes in colorectal surgery at AGH. "If you keep the wound size small, then obviously there is less opportunity for there to be an infection."

In April, Dr. McCormick performed bloodless colorectal surgery on John Tomolonis, 74, of Ohio. With no complications or infections arising after the operation, he recovered and left the hospital after only four days.

"I was sent to AGH from my local hospital because ... they didn't feel that they had the right equipment to do that," said Mr. Tomolonis. "I have been feeling great since my surgery,"

Shortened stays such as these and a reduction in the number of transfusions make bloodless surgery an economically wise choice, too.

"If you reduce the transfusion rate by 5 or 10 percent, you could save a hospital like [AGH] $1 million to $2 million a year," said Dr. Seski.

His techniques are part of an ongoing educational process at AGH. "We have new physicians and personnel coming into the system and are working to properly educate them in the field of bloodless medicine and surgery," he said.

Rob Wennemer is a former intern at the Post-Gazette.
First Published August 20, 2012 12:00 am Read more: http://www.post-gazette.com/stories/news/health/making-the-case-for-bloodless-surgery-649699/#ixzz24AChMjiO

32

JWs And Near Death Experiences

by Cold Steel in

[if gte mso 9]><xml> <w:worddocument> <w:view>normal</w:view> <w:zoom>0</w:zoom> <w:punctuationkerning /> <w:validateagainstschemas /> <w:saveifxmlinvalid>false</w:saveifxmlinvalid> <w:ignoremixedcontent>false</w:ignoremixedcontent> <w:alwaysshowplaceholdertext>false</w:alwaysshowplaceholdertext> <w:compatibility> <w:breakwrappedtables /> <w:snaptogridincell /> <w:wraptextwithpunct /> <w:useasianbreakrules /> <w:dontgrowautofit /> </w:compatibility> <w:browserlevel>microsoftinternetexplorer4</w:browserlevel> </w:worddocument> </xml><!

[endif][if gte mso 9]><xml> <w:latentstyles deflockedstate="false" latentstylecount="156"> </w:latentstyles> </xml><!

[endif][if gte mso 10]> <style> /* style definitions */ table.msonormaltable {mso-style-name:"table normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"times new roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;} </style> <![endif].

TJ Curioso

Not all, near death experiences have a cientifical explanation. There are cases in which blind people, when "resuscitated" by medical staff, report facts that only someone who actually saw these things could do. Other when "get out of their bodies" for a period of time, even reported that their relatives had conversations in remote locations, at the time and / or their reactions to the situation. I do not believe that science has yet explanation for such situations.

100

Post 607: Reject 607 BC if You TRULY Trust the Bible!!!

by Londo111 in

therefore, if the 70 years period is for the destruction of jerusalem and exile at babylon:.

if zedekiah had not rebelled against babylon, had he surrendered during the final siege that lasted two and a half years, then the destruction of jerusalem and the deportation need not have happened.

then in the jubilee year, they were set free and their hereditary land was returned to them.

TJ Curioso

Thanks Londo111!

I invite you all to visit this site and to read the article with the theme:

EVIDENCE THAT THE 1914 A.D. AND 607 B.C. DATES OF JEHOVAH’S WITNESSES ARE WRONG

Here is only the introduction:

- WHY 1914 A.D. IS IMPORTANT TO JEHOVAH’S WITNESSES -

The date 1914 A.D. has played a dominant role in the eschatology of the Jehovah’s Witnesses from its inception in 1879 with the writings of Charles Taze Russell, founder of the Watch Tower Bible and Tract Society. For over a hundred years, Jehovah’s Witnesses have been teaching that 1914 marks the conclusion of a prophetic time period they call “the Times of the Gentiles” or “appointed times of the nations” which they claim began with the fall of Jerusalem in 607/606 B.C.

Prior to 1914, Jehovah’s Witnesses proclaimed that the end of this period would culminate in the destruction of all earthly governments in the “Battle of Armageddon.” 1. With the outbreak of World War I in 1914, it seemed to them that such prophetic declarations by the Watchtower Society were indeed being fulfilled and that the new system of things under Christ’s millennial reign of 1,000 years was just around the corner. Heralding such statements, Jehovah’s Witnesses flocked to the streets, urging prospective converts to join the Watchtower organization in order to avoid the impending doom that they claimed would occur near this date.

When Christ failed to appear in 1914 and World I failed to abolish earthly governments, Joseph F. Rutherford, successor to Charles Taze Russell, enacted a major shift in the way Jehovah’s Witnesses view 1914. No longer was 1914 promoted as the conclusion of the prophetic “time of the end,” 2. but rather as it is seen now, the “beginning” of this period. 3. This major shift in Watchtower chronological doctrine on 1914, has allowed Jehovah’s Witnesses to continue to promote this false date as the time that Christ setup an “invisible” reign in the heavens. They assert that this time period will eventually climax with the end of human governmental rule at the Battle of Armageddon.

-----------------

Read the rest here:

http://4jehovah.org/hidden-facts-about-jehovah-s-witnesses/607-1914-exposed.php

I hope that this article helps has many as possible! See the others articles too in this website.

3

New Study Reveals Wide Variation in Blood Transfusion Practices During Surgery

by TJ Curioso in

new study reveals wide variation in blood transfusion practices opportunity for masimo noninvasive and continuous hemoglobin monitoring to help optimize transfusion decisionsby masimopublished: thursday, jul.

26, 2012 - 6:11 amirvine, calif., july 26, 2012 -- /prnewswire/ -- according to a new study in the july 2012 print edition of anesthesiology, blood transfusion, the most common procedure performed in u.s. hospitals1, has wide variation in frequency by surgical procedure and physician as well as wide variation in the hemoglobin trigger used to help decide whether to transfuse.2 the study also showed a significant number of transfusion decisions are made without laboratory hemoglobin measurements.

the research adds to the growing clinical evidence highlighting the need for improved blood-management strategies.

TJ Curioso

New Study Reveals Wide Variation in Blood Transfusion Practices

Opportunity for Masimo Noninvasive and Continuous Hemoglobin Monitoring to Help Optimize Transfusion Decisions

By Masimo Published: Thursday, Jul. 26, 2012 - 6:11 am

IRVINE, Calif., July 26, 2012 -- /PRNewswire/ -- According to a new study in the July 2012 print edition of Anesthesiology, blood transfusion, the most common procedure performed in U.S. hospitals 1 , has wide variation in frequency by surgical procedure and physician as well as wide variation in the hemoglobin trigger used to help decide whether to transfuse. 2 The study also showed a significant number of transfusion decisions are made without laboratory hemoglobin measurements. The research adds to the growing clinical evidence highlighting the need for improved blood-management strategies. It also underscores the opportunity for noninvasive and continuous total hemoglobin (SpHb ® ) monitoring from Masimo (NASDAQ: MASI) to facilitate optimal transfusion decision making to improve patient safety and reduce costs.

In the study, conducted at Johns Hopkins Hospital in Baltimore, Maryland, researchers collected data on 48,086 surgical patients over 18 months and evaluated blood transfusion frequency and hemoglobin triggers by surgical procedure and physician. A total of 2,981 patients (6.2%) received an intra-operative red blood cell transfusion, with two-thirds of those patients receiving two or more units. Transfusion rates varied up to threefold between different physicians performing the same procedure (p<0.05). The average transfusion hemoglobin trigger used to determine need forblood transfusion varied widely with both surgeons (7.2 g/dL to 9.8 g/dL, p=0.001 and anesthesiologists (7.2 g/dL to 9.6 g/dL, p=0.001). The ending hemoglobin values after the last recorded transfusion also varied widely for both surgeons (8.8 g/dL to 11.8 g/dL, p=0.001) and anesthesiologists (9.0 g/dL to 11.7 g/dL, p=0.0004). A recent laboratory hemoglobin measurement was not available when 31% of transfusion decisions were made.

Blood transfusions carry risks. In a previous meta-analysis of 45 studies evaluating the risks ofblood transfusion, 42 studies showed a significant link to mortality, infection, or adult respiratory distress syndrome. 3 In contrast to the historical belief that withholding transfusions harms patients, multiple randomized controlled trials have now proven that restrictive transfusion practice is safe. 4,5,6 This has led recent transfusion guidelines to focus transfusion decisions on the overall patient condition and to suggest hemoglobin transfusion triggers of 6-7 g/dL for most patients and above 7 g/dL only in select, high-risk patients. 7,8,9

Blood transfusions are also one of the largest cost centers in hospitals. While the material cost of blood ranges from $200 to $300 per unit, the additional costs from storage, labor, and waste result in an actual cost per unit between $522 and $1,183. 10 In addition to the cost of blood itself, each unit of blood transfused increases the cost of care, with even higher costs incurred when patients are transfused at higher hemoglobin levels. 11

A recent systematic evaluation of 494 studies concluded that 59% of transfusions were "inappropriate" based on their impact on patient outcomes. 12 The risks and costs of blood transfusion paired with unnecessary transfusions led the Joint Commission in 2011 to introduce new patient blood management measures that hospitals are being encouraged to adopt as a quality indicator. 13 The new measures include recording the clinical indication for transfusion along with the hemoglobin value of the patient prior to each unit transfused. With the need to stem rising health care expenditures, the Joint Commission and the American Medical Association have targeted blood transfusion procedures as one of the top procedures to reduce in a "National Summit on Overuse" scheduled for September 2012. 14

There is no doubt that clinicians desire the best care for their patients without unnecessary costs, but they are also limited in their precise ability to determine need for transfusion with existing tools. Estimates of blood loss in the operating room can be inaccurate. Researchers at Duke University recently reported estimated surgical blood loss exceeded measured blood loss by more than 40% (860mL vs. 611 mL, p< 0.0001). 15 The likely reason for this discrepancy is the inability to accurately estimate blood loss based on visual inspection of blood and fluid in suction canisters and surgical sponges. While estimating blood loss is challenging and laboratory hemoglobin results are only availably intermittently and are often delayed, transfusion decisions are made in real time. Acknowledging these challenges, the Duke Researchers stated: "Use of bedside hemoglobin concentration devices and continuous, noninvasive hemoglobin monitors may improve transfusion decisions."

Masimo's breakthrough SpHb measurement allows clinicians to noninvasively and continuously monitor hemoglobin. Results of an earlier randomized controlled trial conducted by researchers atMassachusetts General Hospital and Harvard Medical School showed that SpHb helped anesthesiologists reduce the frequency of blood transfusion by 87% (from 4.5% to 0.6%, p=0.03) and quantity of blood by 90% (from 0.1 to 0.01 units per patient, p<0.0001) in 327 patients undergoing orthopedic surgery. 16

Dr. Aryeh Shander, Executive Medical Director at the Institute for Patient Blood Management & Bloodless Medicine Surgery and Chief of Anesthesiology and Critical Care Medicine at Englewood Hospital & Medical Center in New Jersey, stated: "The ability of Masimo's noninvasive hemoglobin technology to continuously monitor hemoglobin during surgeries can offer earlier, real-time information that can result in diagnosis leading to interventions other than transfusion. And fewer unnecessary transfusions can mean improved patient outcomes."

This year Masimo launched the Blood Transfusion Related Cost Reduction guarantee program (BTR-CR, "Better Care") to help hospitals improve patient care and reduce costs. BTR-CR guarantees that a hospital's blood transfusion-related cost reductions will be greater than the cost of SpHb monitoring. For more information, contact 888-44BTRCR or visit BTR-CR.

1 AHRQ, Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 1997 and 2007.

2 Steven M. Frank, M.D., Will J. Savage, M.D., Jim A. Rothschild, M.D., Richard J. Rivers, M.D., Paul M. Ness, M.D., Sharon L. Paul, B.S., M.S., John A. Ulatowski, M.D., Ph.D., M.B.A. "Variability in Blood and Blood Component Utilization as Assessed by an Aesthesia Information Management System." Anesthesiology, July 2012 - Volume 117 - Issue 1 - p 99–106 doi: 10.1097/ALN.0b013e318255e550

3 Marik, P. E. and H. L. Corwin (2008). "Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature." Crit Care Med 36(9): 2667-74.

4 Carson, J. L., M. L. Terrin, et al. (2011). "Liberal or restrictive transfusion in high-risk patients after hip surgery." N Engl J Med 365(26): 2453-62.

5 Hebert, P. C., G. Wells, et al. (1999). "A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group." N Engl J Med 340(6): 409-17.

6 Hajjar, L. A., J.-L. Vincent, et al. (2010). "Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial." JAMA 304(14): 1559-1567.

7 American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies: Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105:198 –208

8 Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, Hebert PC, Anderson GL, Bard MR, Bromberg W, Chiu WC, Cipolle MD, Clancy KD, Diebel L, Hoff WS, Hughes KM, Munshi I, Nayduch D, Sandhu R, Yelon JA, American College of Critical Care Medicine of the Society of Critical Care Medicine, Eastern Association for the Surgery of Trauma Practice Management Workgroup: Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37:3124 –57

9 Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG: 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944 – 82

10 Shander, A.,A. Hofmann, et al. "Activity-based costs of blood transfusions in surgical patients at four hospitals." Transfusion 50(4): 753-65.

11 Murphy, G. J., B. C. Reeves, et al. (2007). "Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery." Circulation 116(22): 2544-52.

12 Shander, A., A. Fink, et al. (2011). "Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes." Transfus Med Rev 25(3): 232-246 e53.

13 Gammon HM, Waters JH, Watt A, Loeb JM, Donini-Lenhoff A: Developing performance measures for patient blood management. Transfusion 2011; 51:2500 –9.

14 Joint Commission Perspectives. The Joint Commission Continues to Study Overuse Issues. Volume 32, Number 5, 2012 : 4-8(5).

15 Hill, S., Broomer, B Stover, J, White, W. (2011). Accuracy of estimated blood loss in spine surgery. American Society of Anesthesiologists Annual Conference, San Diego, CA

16 Ehrenfeld JM, Henneman JP, Sandberg WS. "Impact of Continuous and Noninvasive Hemoglobin Monitoring on Intraoperative Blood Transfusions." American Society Anesthesiologists. 2010;LB05

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET ® , which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO 2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET ® Pulse CO-Oximetry TM technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC TM ), carboxyhemoglobin (SpCO ® ), methemoglobin (SpMet ® ), and Pleth Variability Index (PVI ® ), in addition to SpO 2 , pulse rate, and perfusion index (PI). In 2008, the company introduced Masimo Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring TM , the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO 2 , pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact: Mike Drummond Masimo Corporation Phone: (949) 297-7434 Email:[email protected]

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

SOURCE Masimo

http://www.sacbee.com/2012/07/26/4662456/new-study-reveals-wide-variation.html

4

Anonymous Message to Watchtower

by TJ Curioso in

see here:.

http://youtu.be/bhyl4waps2o.

TJ Curioso

Thanks Cedars!

4

Anonymous Message to Watchtower

by TJ Curioso in

see here:.

http://youtu.be/bhyl4waps2o.

TJ Curioso

See here:

http://youtu.be/BhYL4WAPS2o

6

Engaged Governing body member reverses ruling on oral sex before his honeymoon! Good news!

by Witness 007 in

as we heard my aussie drinking mate mate geoff jackson of the governing body is engaged to a woman less the half his age......ozzie ozzie ozzie....oooooy oooooy ooooy!!!!!!

before we take him on his "aussie bucks night" and leave him handcuffed to a sheep....i have great news.. he told me a new watchtower is coming out next month saying: "elders can no longer police any sexual practices between a husband and wife.." {he then winked and threw me another fosters beer} go you dog yeaaaaaaaah!

just in time for his honeymoon.

TJ Curioso

You are joking, right?